Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022.
COVID-19
Italy
SARS-CoV-2
bivalent mRNA vaccines
effectiveness
elderly population
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
3
3
2023
Statut:
ppublish
Résumé
Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4-5) mRNA vaccine 7-90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4-6 months earlier indicated no significant additional protection (10%; 95% CI: -44 to 44). A second booster vaccination 6 months after the latest infection may be warranted.
Identifiants
pubmed: 36820640
doi: 10.2807/1560-7917.ES.2023.28.8.2300105
pmc: PMC9951255
doi:
Substances chimiques
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Lancet Infect Dis. 2023 Feb;23(2):167-176
pubmed: 36270311
Lancet Infect Dis. 2023 Feb;23(2):148-150
pubmed: 36620968
Lancet Infect Dis. 2023 Jan 18;:
pubmed: 36681084